HCV Immunology CTL, CD8+ T-Cell, Search
Found 8 matching records:
Displaying record number 2336
| H77 Location | NS4b(1758-1766) | NS4b Epitope Map |
| Author Location | NS4(1858-1867) | |
| Epitope | GVAGALVAFK | Epitope Alignment |
| Species (MHC/HLA) | (A3) | |
| Experimental methods | CTL assay, T cell Elispot | |
| Keywords | review |
Notes
- This epitope is from a table of previously published CTL epitopes reviewed by Ward2002. Experimental methods are also listed in the review.
References
Ward2002 S. Ward, G. Lauer, R. Isba, B. Walker, and P. Klenerman. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol, 128(2):195-203, May 2002. PUBMED ID: 11985510. Show all entries for this paper.
Displaying record number 2337
| H77 Location | NS4b(1758-1766) | NS4b Epitope Map |
| Author Location | NS4(1858-1867) | |
| Epitope | VAGALVAFK | Epitope Alignment |
| Species (MHC/HLA) | (A3) | |
| Experimental methods | CTL assay, T cell Elispot | |
| Keywords | review |
Notes
- This epitope is from a table of previously published CTL epitopes reviewed by Ward2002. Experimental methods are also listed in the review.
References
Ward2002 S. Ward, G. Lauer, R. Isba, B. Walker, and P. Klenerman. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol, 128(2):195-203, May 2002. PUBMED ID: 11985510. Show all entries for this paper.
Displaying record number 136
| H77 Location | NS4b(1858-1867) | NS4b Epitope Map |
| Author Location | NS4(1863-1872) | |
| Epitope | GVAGALVAFK | Epitope Alignment |
| Species (MHC/HLA) | human (A3) | |
| Immunogen | HCV infection | |
| Experimental methods | T cell Elispot IFN-γ, T cell Elispot IL-5 | |
| Keywords | Th1, Th2, frequency of response, chronic HCV, Interferon therapy, Ribavirin therapy |
Notes
- The objective of the study was to study the effect of IFN-alpha/ribavirin therapy on type 1 and type 2 HCV-specifc CD4+ and CD8+ T cell responses during the therapy.
- In 3/4 patients therapy-induced viral clearance was associated with a significant augmentation of type 1 CD4+ and CD8+ T cell responses. In the patient who did not respond to the therapy, a significant CD4+ Th2 cell reactivity was not accompanied by augmentation of CD8+ T-cell reactivity.
References
Sreenarasimhaiah2003a J. Sreenarasimhaiah, A. Jaramillo, J. Crippin, M. Lisker-Melman, W. C. Chapman, and T. Mohanakumar. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol, 64(5):497-504, May 2003. PUBMED ID: 12691700. Show all entries for this paper.
Displaying record number 209
| H77 Location | NS4b(1858-1867) | NS4b Epitope Map |
| Author Location | NS4b(1863- genotype 1a) | |
| Epitope | GVAGALVAFK | Epitope Alignment |
| Epitope Name | Peptide 21 | |
| Species (MHC/HLA) | chimpanzee (A3) | |
| Immunogen | HCV infection | |
| Experimental methods | Chromium-release assay, Flow cytometry, Peptide binding, T cell Elispot IFN-γ | |
| Keywords | cross-presentation by different HLA, HLA binding |
Notes
- The purpose of this study was to characterize chimpanzee MHC class I alleles both at the molecular and functional levels.
- 18 different Patr alleles were sequenced. Based on molecular homology between common human alleles and Patr alleles, functional Patr-HLA homology was demonstrated in CTL and IFN-γ ELISPOT assays (CTL isolated from HCV-infected monkeys) on a set of HCV peptides that had been described to be recognized by CTL of HCV-infected humans or chimpanzees.
- 21 HCV epitopes were selected to characterize the chimpanzees' cellular immune responses to HCV.
- Several Patr-A*0501-positive chimpanzees, chimpanzee with a haplotype of Patr-A*0301,A*1501,B*2202 and chimpanzee with a haplotype of Patr-A*0101, A*0301, B*0101, B*0302 mounted IFN-γ response to this (and other) HLA-A3-restricted peptides.
References
Mizukoshi2002 E. Mizukoshi, M. Nascimbeni, J. B. Blaustein, K. Mihalik, C. M. Rice, T. J. Liang, S. M. Feinstone, and B. Rehermann. Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol, 76(12):6093-103, Jun 2002. PUBMED ID: 12021342. Show all entries for this paper.
Displaying record number 2415
| H77 Location | NS4b(1858-1867) | NS4b Epitope Map |
| Author Location | NS4(1863- genotype 1a) | |
| Epitope | GVAGALVAFK | Epitope Alignment |
| Epitope Name | NS4 1863 | |
| Species (MHC/HLA) | human (A3) | |
| Immunogen | HCV infection | |
| Experimental methods | Chromium-release assay, Peptide binding | |
| Keywords | acute HCV, computational epitope prediction, immunodominance, supertype, chronic HCV, Interferon therapy, HLA binding, conserved epitopes, resolved HCV |
Notes
- This study, using a motif search and HLA-binding affinity protocol, identified eight new HLA-A3 supertype-restricted and one HLA-B7 supertype-restricted CTL epitopes, in structural and nonstructural HCV proteins, that were recognized by both acute and chronic HCV.
- Peptides were selected based on the HLA-A3 supermotif (AILMVSTG in position 2, RK at C-terminus) and on the HLA-B7 supermotif (P in position 2 and AILMVFWY at C-terminus).
- All peptides were immunogenic in at least 1 patient. Responses were observed in patients infected by HCV subtype 1a, 1b, 2b, 3a.
- The total number of immunogenic HLA-A3 peptides in individual patients correlated inversely with ALT activity. Patients with ongoing IFN therapy displayed CTL responsiveness to more peptides than the patients without a therapy.
- Patients with spontaneous HCV clearance had a stronger response to the HLA-B7 peptide LPGCSFSIF than those with chronic hepatitis. CTL responsiveness to the HLA-B7 peptide increased over time in 2 patients who cleared HCV.
- This peptide (GVAGALVAFK) bound with 50% inhibitory concentration < 500 nM to the following HLA molecules: A*0301, A*1101, A*6801.
- This peptide (GVAGALVAFK) was 85% conserved among the following HCV sequences: HPCCGAA, HPCPLYPRE, HCV-H-CMR, HCV-J1, HPCGENANTI, HPCGENOM, HPCHUMR, HPCJCG, HPCJTA, HCV-J483, HCV-JK1, HCV-N, HPCPOLP, HCV-J8.
- This peptide was the most frequently immunogenic (recognized by 4/12 patients). The truncated peptide VAGALVAFK (lacking N-terminal G residue) was recognized by only 1 patient out of these 4.
References
Chang1999 K. M. Chang, N. H. Gruener, S. Southwood, J. Sidney, G. R. Pape, F. V. Chisari, and A. Sette. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol, 162(2):1156-64, Jan 1999. PUBMED ID: 9916747. Show all entries for this paper.
Displaying record number 137
| H77 Location | NS4b(1859-1867) | NS4b Epitope Map |
| Author Location | NS4(1864-1872) | |
| Epitope | VAGALVAFK | Epitope Alignment |
| Species (MHC/HLA) | human (A3) | |
| Immunogen | HCV infection | |
| Experimental methods | T cell Elispot IFN-γ, T cell Elispot IL-5 | |
| Keywords | Th1, Th2, frequency of response, chronic HCV, Interferon therapy, Ribavirin therapy |
Notes
- The objective of the study was to study the effect of IFN-alpha/ribavirin therapy on type 1 and type 2 HCV-specifc CD4+ and CD8+ T cell responses during the therapy.
- In 3/4 patients therapy-induced viral clearance was associated with a significant augmentation of type 1 CD4+ and CD8+ T cell responses. In the patient who did not respond to the therapy, a significant CD4+ Th2 cell reactivity was not accompanied by augmentation of CD8+ T-cell reactivity.
References
Sreenarasimhaiah2003a J. Sreenarasimhaiah, A. Jaramillo, J. Crippin, M. Lisker-Melman, W. C. Chapman, and T. Mohanakumar. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol, 64(5):497-504, May 2003. PUBMED ID: 12691700. Show all entries for this paper.
Displaying record number 210
| H77 Location | NS4b(1859-1867) | NS4b Epitope Map |
| Author Location | NS4b(1864- genotype 1a) | |
| Epitope | VAGALVAFK | Epitope Alignment |
| Epitope Name | Peptide 22 | |
| Species (MHC/HLA) | chimpanzee (A3) | |
| Immunogen | HCV infection | |
| Experimental methods | Chromium-release assay, Flow cytometry, Peptide binding, T cell Elispot IFN-γ | |
| Keywords | cross-presentation by different HLA, HLA binding |
Notes
- The purpose of this study was to characterize chimpanzee MHC class I alleles both at the molecular and functional levels.
- 18 different Patr alleles were sequenced. Based on molecular homology between common human alleles and Patr alleles, functional Patr-HLA homology was demonstrated in CTL and IFN-γ ELISPOT assays (CTL isolated from HCV-infected monkeys) on a set of HCV peptides that had been described to be recognized by CTL of HCV-infected humans or chimpanzees.
- 21 HCV epitopes were selected to characterize the chimpanzees' cellular immune responses to HCV.
- Several Patr-A*0501-positive chimpanzees, chimpanzee with a haplotype of Patr-A*0301,A*1501,B*2202, chimpanzee with a haplotype of Patr-A*0101, A*0301, B*0101, B*0302 and chimpanzee with a haplotype of Patr-A*1401,B*0101,B*0901 mounted IFN-γ response to this (and other) HLA-A3-restricted peptides.
References
Mizukoshi2002 E. Mizukoshi, M. Nascimbeni, J. B. Blaustein, K. Mihalik, C. M. Rice, T. J. Liang, S. M. Feinstone, and B. Rehermann. Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol, 76(12):6093-103, Jun 2002. PUBMED ID: 12021342. Show all entries for this paper.
Displaying record number 2416
| H77 Location | NS4b(1859-1867) | NS4b Epitope Map |
| Author Location | NS4(1864- genotype 1a) | |
| Epitope | VAGALVAFK | Epitope Alignment |
| Epitope Name | NS4 1864 | |
| Species (MHC/HLA) | human (A3) | |
| Immunogen | HCV infection | |
| Experimental methods | Chromium-release assay, Peptide binding | |
| Keywords | acute HCV, computational epitope prediction, supertype, chronic HCV, Interferon therapy, HLA binding, conserved epitopes, resolved HCV |
Notes
- This study, using a motif search and HLA-binding affinity protocol, identified eight new HLA-A3 supertype-restricted and one HLA-B7 supertype-restricted CTL epitopes, in structural and nonstructural HCV proteins, that were recognized by both acute and chronic HCV.
- Peptides were selected based on the HLA-A3 supermotif (AILMVSTG in position 2, RK at C-terminus) and on the HLA-B7 supermotif (P in position 2 and AILMVFWY at C-terminus).
- All peptides were immunogenic in at least 1 patient. Responses were observed in patients infected by HCV subtype 1a, 1b, 2b, 3a.
- The total number of immunogenic HLA-A3 peptides in individual patients correlated inversely with ALT activity. Patients with ongoing IFN therapy displayed CTL responsiveness to more peptides than the patients without a therapy.
- Patients with spontaneous HCV clearance had a stronger response to the HLA-B7 peptide LPGCSFSIF than those with chronic hepatitis. CTL responsiveness to the HLA-B7 peptide increased over time in 2 patients who cleared HCV.
- This peptide (VAGALVAFK) bound with 50% inhibitory concentration < 500 nM to the following HLA molecules: A*0301, A*1101, A*6801.
- This peptide (VAGALVAFK) was 85% conserved among the following HCV sequences: HPCCGAA, HPCPLYPRE, HCV-H-CMR, HCV-J1, HPCGENANTI, HPCGENOM, HPCHUMR, HPCJCG, HPCJTA, HCV-J483, HCV-JK1, HCV-N, HPCPOLP, HCV-J8.
- This peptide (VAGALVAFK) was recognized by 1 patient, while a longer peptide GVAGALVAFK (with G on N-terminus) was the most frequently immunogenic (recognized by 4/12 patients).
References
Chang1999 K. M. Chang, N. H. Gruener, S. Southwood, J. Sidney, G. R. Pape, F. V. Chisari, and A. Sette. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol, 162(2):1156-64, Jan 1999. PUBMED ID: 9916747. Show all entries for this paper.
